Risk and protective factors of non-alcoholic fatty liver disease in paediatric obesity: A nationwide nested

Resthie R Putri1, Thomas Casswall1, Emilia Hagman1

  • 1Division of Paediatrics, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden.

Clinical Obesity
|December 7, 2021
PubMed

Insights

Children with severe obesity, impaired fasting glucose, and high triglycerides face higher non-alcoholic fatty liver disease (NAFLD) risks. Successful obesity treatment significantly reduces NAFLD risk, even in severe cases.

Area of Science:

  • Pediatrics
  • Hepatology
  • Metabolic Disorders

Background:

  • Non-alcoholic fatty liver disease (NAFLD) risk varies among children with obesity.
  • Understanding risk factors in pediatric obesity is crucial for early intervention.

Purpose of the Study:

  • To investigate the impact of obesity severity, metabolic parameters, and treatment outcomes on NAFLD risk in pediatric obesity.
  • To identify key predictors of NAFLD development in children undergoing obesity treatment.

Main Methods:

  • Nested case-control study using the Swedish Childhood Obesity Treatment Register (BORIS) and National Patient Register.
  • Matched 76 NAFLD cases with 241 controls based on sex and age at treatment initiation.
  • Analyzed the association between obesity severity (BMI SDS), metabolic factors (IFG, triglycerides), and NAFLD risk.

Main Results:

  • Severe obesity (OR: 3.15), impaired fasting glucose (IFG) (OR: 5.29), and high triglycerides (OR: 2.33) significantly increased NAFLD risk.
  • Weight gain during treatment correlated with higher NAFLD risk (OR: 4.67 per BMI SDS unit).
  • Weight loss of ≥0.25 BMI SDS units independently reduced NAFLD risk (OR: 0.09).

Conclusions:

  • Severe obesity, IFG, and high triglycerides are significant risk factors for NAFLD in pediatric obesity.
  • Effective obesity treatment, particularly weight loss, can nearly eliminate NAFLD risk, irrespective of initial obesity severity or metabolic status.

Related Concept Videos

Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
683
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
15
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
13
Overview of Lipid Metabolism01:24

Overview of Lipid Metabolism

Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
2.9K
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
18
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
27